Chagas' disease, caused by the unicellular parasite Trypanosoma cruzi, affects millions of people in South and Central America. Occasional cases have also been reported in the United States (20, 25, 31) . Laboratory animals and patients in the acute stage of this disease exhibit immunosuppression, which is thought to diminish resistance to the establishment and dissemination of the organism in the host. In acutely infected mice, this suppression is manifested in many forms, including reduced lymphoproliferation in vitro in response to mitogens or trypanosomal antigens and impaired primary and secondary antibody responses and delayed hypersensitivity reactions (5-8, 13-15, 22, 24) . In the mouse model system of Chagas' disease, these effects have been attributed to increased suppressive activities by splenic T cells (22) or macrophages (8, 15) , reduced levels of T cells (13) , and decreased interleukin-2 (IL-2) production (12, 26, 27) . In patients with Chagas' disease, immunosuppression has been reported to occur in the acute and subacute phases, at least in the form of suppressed cellular immunity (28, 30) . Whereas all of these studies have focused on the immunological alterations that occur in infected hosts, our understanding of the underlying mechanism(s) is minimal. While trying to develop an in vitro system to explore this mechanism, we were able to show that the presence of T. cruzi in cultures of lymphoid cells from either normal mice (17) or human volunteers (1, 2) markedly suppresses mitogen-induced lymphoproliferation. Whereas the parasite inhibits * Corresponding author. expression of IL-2 receptors (IL-2R) by human peripheral blood mononuclear cells (hPBMC) in this system. it does not alter production of interleukin-1 (IL-1). IL-2. or gamma interferon (2; L. A. Beltz, G. Sonnenfeld. and F. Kierszenbaum, unpublished data). Some of these findings represent glaring differences between mouse and human cells with respect to T. cruzi-induced immunosuppression. Thus, the capacities of mitogen-stimulated mouse cells to produce IL-2 and gamma interferon in the presence of T. cruzi (Beltz et al., unpublished data) are significantly diminished, but production of these cytokines by hPBMC under similar conditions is not affected (2; Beltz et al., unpublished data). Furthermore, exogenous IL-2 restores the responsiveness of lymphocytes from infected mice both in vitro and in vivo (5, 27) and corrects the in vitro suppressive effect of T. cruzi on normal mouse lymphocytes (2) but fails to do so in T. cruzi-induced suppression of hPBMC in vitro (2) . Given these differences, it is important to characterize the suppressive effects of T. cruzi on human lymphocytes. The kinetic studies on the expression of several human lymphocyte activation markers that were conducted in this work had two main purposes. One was to define the earliest time at which manifestations of T. cruzi-induced suppression occur in hPBMC. The other one was to establish whether parasitemediated suppression involved alteration of lymphocyte activation markers besides IL-2R. Selected for these purposes were the early activation antigen (EA1) and transferrin receptors (TfR), known to be first expressed by human lymphocytes at 4 to 6 (11) and 20 to 24 (10, 21) h after activation, respectively. These times compare with 6 to 8 h for the appearance on the activated lymphocyte surface of Tac (4, 9, 16, 23) , an epitope of the p55 chain of IL-2R.
MATERIALS AND METHODS Parasites. T. cruzi trypomastigotes (Tulahuen isolate) were isolated from the blood of Crl-CD1 (ICR) Swiss mice (Charles River Breeding Laboratories, Inc., Portage, Mich.) infected intraperitoneally 2 weeks previously with 2 x 105 organisms. The parasites were purified by centrifugation (350 x g, 20°C, 45 min) over a mixture of Ficoll-Hypaque with a density of 1.077 (3), followed by chromatography through DEAE-cellulose (18) . After two washings with RPMI 1640 medium (GIBCO Laboratories, Grand Island, N.Y.) containing 100 U of penicillin and 100 jig of streptomycin per ml, the parasites were suspended at the desired concentrations in the same medium supplemented with 5% heat-inactivated (56°C, 20 min) fetal bovine serum. The suspension consisted of 100% trypomastigotes (>99% viable).
hPBMC. Normal hPBMC from healthy volunteers were purified by density gradient centrifugation (350 x g, 20°C, 45 min) over a mixture of Ficoll-Hypaque with a density of 1.077. After three washings with RPMI 1640 medium, the cells were suspended at the desired concentration in RPMIfetal bovine serum. Cell viability, determined by trypan blue exclusion, was >99%.
Reagents. Phytohemagglutinin (PHA) was purchased from Sigma Chemical Co., St. Louis, Mo. Anti-Tac, a monoclonal antibody (MAb) specific for an epitope of the p55 chain of human IL-2R (29) , and anti-EA1, a MAb which recognizes an early human lymphocyte activation marker (11), were generous gifts from T. A. Waldmann (National Institutes of Health, Bethesda, Md.) and S. M. Fu (Oklahoma Medical Research Foundation, Oklahoma City, Okla.), respectively. MAbs that recognize epitopes of human TfR (OKT9) and an epitope of the T cell antigen receptor complex T3-Ti (OKT3, anti-CD3) (19) were purchased from Ortho Diagnostics, Inc., Raritan, N.J.
Lymphoproliferation assay. In all experiments, parallel cultures were set up to monitor the effects of T. cruzi on stimulated hPBMC. Cultures of hPBMC in RPMI-fetal bovine serum were incubated (5% CO2; 96-well plates) at 37°C a m.8 for 96 h (final concentration, 1.25 x 106 cells per ml) with or without T. criuzi (5 x 106 organisms per ml) in the presence or absence of optimal concentrations of PHA (5 jxg/ml) or anti-CD3 (25 ng/ml). In all cases, the finail culture volume was adjusted to 100 p. Ill.) at 24 h before termination by automated harvesting.
Radioactivity was determined in a liquid scintillation counter. The results were expressed as mean counts per minute ± one standard deviation. However, results for the lymphoproliferation assays are not shown because, had they failed to demonstrate significant suppression, the parallel flow cytometric analyses (see below) would not have been performed. The effects of T. cruzi on the proliferation of mitogen-stimulated hPBMC have been described in detail elsewhere (2 presence or absence of T. criuzi. The logarithm of fluorescence intensities was distributed over 256 channels.
RESULTS
Kinetics of IL-2R expression by hPBMC cocultured with T.
cruzi. Previous flow cytometry studies with anti-Tac established that IL-2R expression by PHA-or anti-CD3-stimulated hPBMC is suppressed by T. criuzi at 48 h after activation (2). The results of an initial kinetic study (Fig. la, panels A, B, and C) confirmed this observation and showed that the effect was demonstrable on PHA-stimulated hPBMC at 24 and 36 h as well. At all of these times, the hPBMC population cocultured with T. cruzi was found to contain significantly lower proportions of IL-2R+. In addition, the surface density of Tac antigen on IL-2R+ cells was markedly reduced, as denoted by significant decreases in fluorescence intensity with respect to the values obtained with PHAstimulated cells cultured in the absence of parasites. To establish whether these inhibitory effects occurred at times earlier than 24 h, we performed additional experiments.
harvesting the hPBMC at 6, 12, and 24 h after stimulation. A typical set of results is shown in Fig. la (panels D, E, and F). demonstrating significant inhibition of IL-2R expression as early as 12 h, with borderline effects occurring at 6 h. To examine whether this effect was also produced under conditions known to mimic antigen-induced lymphocyte activation (16), we performed similar experiments with anti-CD3 as the mitogenic stimulus. The kinetic pattern of suppression of IL-2R expression under these conditions was essentially the same as that seen when PHA was used (Fig. 2) . Effects of T. cruzi on expression of other markers of human lymphocyte activation. To establish whether the suppressive effects of T. cruzi on activated human lymphocytes were confined to IL-2R expression or were a part of a wider phenomenon involving alterations in the expression of other markers, we monitored the kinetics of expression of EAI and TfR. Expression of EAI was readily demonstrable on either PHA-or anti-CD3-activated hPBMC at all tested times after 6 h (Fig. 3) . The presence of the parasite appeared to have had no effect on EAI expression, since there was no significant difference in either the percentage of EAl + cells (Fig. 3) or the surface density of the marker (data not shown). In contrast, expression of TfR after triggering with PHA or anti-CD3 was markedly inhibited by the presence of T. ci-izi (Fig. 4) We previously reported markedly suppressed expression of IL-2R expression by T. cruzi at 48 h after lymphocyte activation (2) . The present kinetic studies place the earliest manifestation of suppression by the parasite as early as 12 h after activation, with borderline effects at 6 h. The suppressive effect at 12 h was documented by decreases in both the percentage of IL-2R+ cells and Tac antigen density on the surface of positive cells. These findings and the time of their occurrence demonstrated the ability of the parasite to affect an early event(s) during lymphocyte activation. Interestingly. these early alterations induced by T. crIlZi are followed by both impaired expression of TfR (Fig. 4) and marked inhibition of lymphocyte proliferation (1, 2) . Expression of both IL-2R and TfR is required for lymphocytes to proceed in their division cycle (4, 10, 11, 16, 19, 21, 23) cyte activation are altered by the parasite, they do not define the precise mechanisms which affect the suppression of IL-2R and TfR. These mechanisms could involve alterations in transcription of the genes that code for receptor proteins, mRNA stability or translation, receptor protein transport to the lymphocyte membrane, and/or increased receptor shedding. These possibilities, as well as identification of the parasite factor(s) that mediates the suppressive effect, are currently receiving attention in our laboratories.
Finally, it is worth mentioning that exploration of the mechanism by which T. criuzi induces suppression of lymphocyte functions could also help advance our understanding of the early regulatory events that govern lymphocyte activation.
